Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Diabetic Retinopathy

59 clinical trials

70 products

3 drugs

Clinical trial
CRIMSON: A Multicentre, Randomised, Sham-controlled (and Active Controlled in the USA), Double-masked, 72-week Trial to Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal BI 764524 in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
BI 764524
Product
Aflibercept
Clinical trial
A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Placebo
Product
OPL-0401
Product
EYP-1901
Clinical trial
A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Product
MB-102
Product
Fluorescein sodium
Product
MB-102 and Zeiss FF450
Clinical trial
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
Status: Completed, Estimated PCD: 2023-12-29
Product
Vehicle Control
Product
OTT166
Product
Vehicle control
Clinical trial
Screening And Detecting Eye Diseases With Hybrid Deep Learning Algorithms From Fundus Images And Validation Of Automated Artificial Intelligence Algorithm
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Mydriatic Agent
Product
Fluorescein sodium and Zeiss FF450 fundus camera
Clinical trial
Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Ranibizumab
Product
Lucentis
Product
RG7774
Clinical trial
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Status: Completed, Estimated PCD: 2023-07-19
Clinical trial
A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Status: Active (not recruiting), Estimated PCD: 2023-10-30
Product
Brolucizumab
Clinical trial
A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Status: Active (not recruiting), Estimated PCD: 2024-04-25
Product
Runcaciguat
Product
Fluorescein sodium + Zeiss FF450
Product
MB-102 and Zeiss FF450 fundus camera
Product
Fluorescein sodium + Zeiss FF450 fundus camera
Clinical trial
A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-687 Injections and to Evaluate the Efficacy and Safety of THR-687 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)
Status: Terminated, Estimated PCD: 2022-06-29
Product
THR-687
Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]
Status: Completed, Estimated PCD: 2022-11-22
Product
2E11 vg/eye of ADVM-022
Product
AKST4290
Clinical trial
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Status: Terminated, Estimated PCD: 2021-12-09
Product
6E11 vg/eye of ADVM-022
Clinical trial
A Clinical Trial Collecting Data From Routine Ophthalmological Examinations of Patients Who Were Randomized to Either Finerenone or Placebo in the Two Bayer-sponsored Phase 3 Clinical Trials FIDELIO-DKD and FIGARO-DKD to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic Retinopathy
Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
A First-in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal dOses (Open Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of Multiple intravitReal Dosing (Single-masked, raNdomized, Sham-controlled) of BI 764524 in panretinaL Photocoagulation (PRP) Treated proLiferative Diabetic Retinopathy (PDR) Patients With Diabetic Macular Ischemia (DMI) - the HORNBILL Study
Status: Completed, Estimated PCD: 2023-04-28
Clinical trial
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Completed, Estimated PCD: 2019-01-09
Product
Finerenone
Product
Tangningtongluo
Product
Calcium dobesilate
Clinical trial
Clinical Study on the Efficacy and Safety of Tangningtongluo Tablet in Treating Non Proliferative Diabetic Retinopathy - The Syndrome of Yin Asthenia Generating Intrinsic Heat and Eye Collateral Stasis
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Product
AKB-9778
Product
MS-553
Product
4D-150
Clinical trial
A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)
Status: Recruiting, Estimated PCD: 2028-02-29
Clinical trial
Assessment of EyeArt Performance With Retinal Cameras
Status: Completed, Estimated PCD: 2022-08-19
Product
RC28-E
Clinical trial
A Randomized, Open-label, Multicenter Study of the Efficacy and Safety of RC28-E Injection in Subjects With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device
Status: Completed, Estimated PCD: 2023-03-31
Product
APX3330
Clinical trial
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via a Single Suprachoroidal Space (SCS) Injections in Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME)(ALTITUDE)
Status: Recruiting, Estimated PCD: 2024-05-01
Product
RGX-314
Product
Topical Steroid
Clinical trial
A Prospective Observational Study Conducted in France to Describe Routine Clinical Practice for Treatment naïve or Previously Treated Patients With Diabetic Macular Edema (DME) Who Are Starting IVT Aflibercept
Status: Completed, Estimated PCD: 2019-08-12
Clinical trial
A First in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal Doses (oPen Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of mulTiple Intravitreal Doses (Double-masked, RandomIzed, Sham-controlleD) of BI 765128 in Panretinal photocoaGulation (PRP) Treated Diabetic rEtinopathy (DR) Patients With Diabetic Macular Ischemia (DMI) - the PARTRIDGE Study
Status: Completed, Estimated PCD: 2023-08-07
Product
BI 765128
Clinical trial
A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy
Status: Active (not recruiting), Estimated PCD: 2022-10-03
Product
Intravitreal Ranibizumab
Product
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Clinical trial
A Phase 2a Study to Evaluate Safety and Tolerability After Single Administration of PER-001 Intravitreal Implant in Participants With Diabetic Retinopathy
Status: Recruiting, Estimated PCD: 2024-11-30
Product
PER-001
Clinical trial
A Long-Term Follow-Up Study of ADVM-022 in Diabetic Macular Edema- INFINITY Extension
Status: , Estimated PCD: 2026-03-01
Product
ADVM-022
Product
THR-149
Clinical trial
A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-149 Injections and to Evaluate the Efficacy and Safety of THR-149 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)
Status: Completed, Estimated PCD: 2023-09-28
Product
THR-149 + Aflibercept
Product
Aflibercept + THR-149
Clinical trial
Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2026-03-20
Product
Faricimab
Clinical trial
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Generation of inducible pluripotent stem cells
Clinical trial
Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Melatonin
Clinical trial
INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy (INSPIRE) Study
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Ketorolac
Clinical trial
A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes
Status: Completed, Estimated PCD: 2023-11-17
Product
Fenofibrate
Clinical trial
Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography
Status: Completed, Estimated PCD: 2023-03-15
Product
Bevacizumab
Clinical trial
A Prospective, Randomized Study on Intravitreal Ozurdex for Preventing Recurrent Vitreous Hemorrhage Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
Status: Completed, Estimated PCD: 2016-04-01
Product
Dexamethasone
Clinical trial
A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Product
Diquafosol
Product
0.1% Hyaluronate
Clinical trial
A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Product
CD34+ Bone Marrow Stem Cells
Clinical trial
Treating Early Stage Diabetic Retinopathy
Status: , Estimated PCD: 2027-12-31
Product
Sinemet
Drug
placebo
Clinical trial
Anatomical and Functional Outcomes of Use of Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy
Status: Completed, Estimated PCD: 2023-11-01
Product
Methotrexate
Clinical trial
Pilot Study of the Evaluation of Sirolimus in the Treatment of Diabetic Macular Edema
Status: Completed, Estimated PCD: 2011-01-01
Product
Sirolimus
Clinical trial
A Phase 2 Study to Evaluate the Safety and Treatment Effect of Intravitreal AVD-104 in Participants With Diabetic Macular Edema
Status: Terminated, Estimated PCD: 2024-04-05
Product
AVD-104
Clinical trial
Evaluation of the Relationship Between SLMAP and EPO Genetic Polymorphism and the Risk of Diabetic Retinopathy in Egyptian Diabetic Patients: A Case-Control Study
Status: Completed, Estimated PCD: 2023-04-30
Product
SLMAP and EPO genetic polymorphism
Clinical trial
A Study on the Treatment Strategy of Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Status: Completed, Estimated PCD: 2022-12-31
Drug
anti-VEGF
Clinical trial
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
Status: Recruiting, Estimated PCD: 2025-03-01
Product
foselutoclax
Clinical trial
LXR as a Novel Therapeutic Target in DR
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Blood Draw
Clinical trial
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time Optical Coherence Tomography During Operation
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Clinical Trial to Evaluate the Safety and Efficacy of Levosulpiride to Improve Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.
Status: Recruiting, Estimated PCD: 2025-06-01
Product
DME lactose
Product
DME Levosulpiride
Product
DR lactose
Product
Levosulpiride
Product
DR vitrectomy lactose pill
Product
DME
Product
DME plus Ranibizumab + Levosulpiride
Clinical trial
A Randomized, Double-masked, Sham-controlled Study to Evaluate the Efficacy of Peri-operative Farcimab in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Product
Sham Treatment
Clinical trial
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Completed, Estimated PCD: 2020-05-01
Clinical trial
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)
Status: Completed, Estimated PCD: 2010-10-01
Product
ranibizumab
Clinical trial
Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab
Status: Completed, Estimated PCD: 2020-12-01
Drug
aflibercept
Clinical trial
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening
Status: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.
Status: Terminated
Clinical trial
Comparison of the Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Using OCTA
Status: Terminated, Estimated PCD: 2022-09-01
Clinical trial
Intravitreal Bevacizumab vs Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A One-year Prospective, Contralateral Eye Study
Status: Withdrawn, Estimated PCD: 2006-03-01
Clinical trial
A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Inert lactose placebo